Keywords: SNPC; Near-infrared; Phototransistor; Active layer structures; SnPc;
مقالات ISI SNPC (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: SNPC; α-syn; alpha-synuclein; CNS; central nervous system; PD; Parkinson disease; CX3CR1; fractalkine receptor; CCR2; C-C chemokine receptor type 2; CCL2; C-C chemokine ligand 2; SNpc; substantia nigra pars compacta; GWAS; genome wide association studies; MHCI
Keywords: SNPC; 6-OHDA; 6-hydroxydopamine; L-DOPA; L-3,4-dihydroxyphenylalanine; MB; methylene blue; MPP+; 1-methyl-4-phenylpyridinium; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; OD; optical density; p; probenecid; PD; Parkinson's disease; SNpc; substantia nig
Keywords: SNPC; AD; Alzheimer's disease; DA; dopamine; DAergic; dopaminergic; hMAO-A; human monoamine oxidase A; hMAO-B; human monoamine oxidase B; HRP; horseradish peroxidase; IC50; the half maximal inhibitory concentration; i.p.; intraperitoneal; Ki; inhibition const
Keywords: SNPC; AcH; acetaldehyde; CTIQs; catechol isoquinolines; DA; dopamine; DMDHIQ+; 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion; ISOP; isoproterenol; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+; 1-Methyl-4-phenylpyridinium; N-Me-Sal; N-methyl-salsolino
Keywords: SNPC; BDI; Beck's Depression Inventor; Cp; ceruloplasmin; CSI; copper status indexes; FAB; Frontal Assessment Battery; H&Y; Hoehn and Yahr stage; HADS; Hospital Anxiety and Depression Scale; IL-6; interleukin-6; NMS PD; Non-Motor Symptoms Scale for Parkinsonâ
Keywords: SNPC; AD; Alzheimer's disease; Control-i; implanted controls; Control-p; physiological controls; d-AMPH; d-amphetamine; EEG; electroencephalographic; EMG; electromyographic; Hipp; hippocampus; HVS; high voltage sleep spindle; IBO; ibotenic acid; LDT; laterodo
Keywords: SNPC; PD; Parkinson's disease; iPSCs; induced pluripotent stem cells; hiPSCs; human induced pluripotent stem cells; PSCs; pluripotent stem cells; DA; dopamine; mDA; midbrain dopamine; fVM; fetal ventral mesencephalon; hESCs; human embryonic stem cells; SNpc;
Keywords: SNPC; Aβ; amyloid β peptide; AD; Alzheimerʹs Disease; ALS; amyotrophic lateral sclerosis; Amb; Amphotericin B; BBB; blood-brain barrier; CJD; Creutzfeld Jakob disease; CSF; cerebral spinal fluid; DCS; D-Cycloserine; DOX; Doxorubicin; GA; Geldanamycin; GAPDH;
Keywords: SNPC; DA; dopamine; i.c.v; intra-cerebro-ventricular; l-dopa; levodopa; MPTP; 1 méthyl-4-phenyl-1,2,3,6 terahydropyridine; 6-OHDA; 6-hydroxydopamine; PD; Parkinson's disease; SMBS; sodium metabisulfite; SNpc; substantia nigra pars compacta; Parkinson's disease
Keywords: SNPC; 3-HK; 3-hydroxykynurenine; 6-OHDA; 6-hydroxydopamine; A; Amygdala; ACMSD; 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase; AD; Alzheimer's disease; AD; Anterodorsal nucleus (Thalamus); α-syn; Alpha-synuclein; CCL2; Chemokine (CC motif) ligand 2;
Keywords: SNPC; 2-AI; 2-aminoindane; 2C-B; 2,5-dimethoxy-4-bromophenethylamine; 5-IAI; 5-iodo-2-aminoindane; COMT; catechol-O-methyl transferase; CPP; conditioned place preference; DAT; dopamine transporter; DIO; diet-induced obese; DMT; N,N-dimethyltryptamine; EAAT2; ex
Keywords: SNPC; Aβ; beta-amyloid peptide; AAV; adeno-associated virus; ABAD; amyloid-beta-binding alcohol dehydrogenase; AD; Alzheimer's disease; ALP; autophagy-lysosome pathways; Apaf-1; apoptic protease-activating factor 1; APP; amyloid precursor protein; AICD; APP in
Keywords: SNPC; Parkinson's disease; Striatum; Rotenone; Phospholipids; Dye-lipid complex; PD; Parkinson's disease; AD; Alzheimer's disease; DA; Dopaminergic neuron; SNpc; Substantia nigra pars compacta; ROT; Rotenone; DMSO; Dimethyl sulfoxide; PLs; Phospholipids; PC; Ph
Keywords: SNPC; PD; Parkinson's disease; AD; Alzheimer's disease; ROS; reactive oxygen species; SNpc; substantia nigra pars compacta; MnSOD; manganese superoxide dismutase; CuSOD; copper superoxide dismutase; NO; nitric oxide; O2â; superoxide anion; ONOOâ; peroxy
Keywords: SNPC; BDNF; brain-derived neurotrophic factor; DA; dopamine; DAT; dopamine transporter; DL; dorsolateral; EAAC1; excitatory amino acid carrier 1; GFAP; glial fibrillary acidic protein; GLAST; glutamate aspartate transporter; GLT-1; glutamate transporter 1; IHC;
Keywords: SNPC; PD; Parkinson's disease; SNpc; substantia nigra pars compacta; LB; Lewy bodies; αSyn; αSynuclein; ER; endoplasmic reticulum; ERAD; ER-Associated Degradation; PINK1; PTEN-induced putative kinase 1; ATP13A2; lysosomal P-type transport ATPase; LRRK2; leuci
Keywords: SNPC; PD; Parkinson's disease; SNpc; Substantia Nigra pars compacta; αSyn; α-synuclein; VTA; ventral tegmental area; UPS; ubiquitin proteasome systems; HAT; histone acetyltransferase; HDAC; histone deacetylase; HDACI; histone deacetylase inhibitor; TH; tyro
Keywords: SNPC; Sleep regulation; Parkinson's disease; Dopamine; Pedunculopontine nucleus; Substantia nigra pars compacta; Striatum; ChAT; Choline Acetyltransferase; DHPG; 3, 4-dihydroxyphenylethyleneglycol; DMSO; Dimethylsulfoxide; DOPAC; 3,4-dihydroxyphenylacetic acid;
Keywords: SNPC; 2-AG; 2-arachidonoyl-glycerol; AEA; anandamide; CB1; cannabinoid receptor type 1; CB2; cannabinoid receptor type 2; CNS; central nervous system; DOPAC; 3,4-Dihydroxyphenylacetic acid; DA; dopamine; D2; dopamine receptor subtype 2; ECS; endocannabinoid sys
Keywords: SNPC; PD; Parkinson's disease; MPTP; 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine; TH; tyrosine hydroxylase; PSD-95; post-synaptic density protein 95; SNpc; substantia nigra pars compacta; Parkinson's disease; Exercise; Synapse; Dendritic spine;
Keywords: SNPC; α-Syn; alpha-synuclein; CBE; conduritol-B-epoxide; CCCP; carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; CS; citrate synthase; Cx I; mitochondrial respiratory chain complex I; DA; dopaminergic; DIV; day in vitro; DMSO; dimethyl sulfoxide; EDTA; eth
Keywords: SNPC; ARND; age related neurodegenerative diseases; AD; Alzheimer's disease; ALS/PDC; amyotrophic lateral sclerosis-Parkinsonism dementia complex of Guam; BBB; blood brain barrier; BMAA; β-methylamino-l-alanine; CNS; central nervous system; CSF; cerebrospina
Keywords: SNPC; AKT; protein kinase B; BBB; blood-brain barrier; BDNF; brain-derived neurotrophic factor; CNS; central nervous system; DA; dopamine; DAB; diaminobenzidine; 78-DHF; 7,8-dihydroxyflavone; DL; dorsolateral; ECF; enhanced chemifluorescence; EDTA; ethylenedi
Keywords: SNPC; PD; Parkinson's disease; MPP+; 1-methyl-4-phenylpyridinium ion; DAT; dopamine transporter; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNpc; substantia nigra pars compacta; DOPAC; 3,4-dihydroxyphenylacetate; HVA; homovanillic acid; ODEs; ordinary
Keywords: SNPC; ACh; acetylcholine; AAV; adeno-associated virus; AgRP; agouti-related protein; ArchT; archaerhodopsin; BAC; bacterial artificial chromosomes; ChRs; channelrhodopsins; DBS; deep brain stimulation; DREADDs; designer receptors exclusively activated by design
Keywords: SNPC; Antioxidant gene therapy; Brain ischemia; Neurodegenerative disorders; Oxidative stress; Virus-mediated gene delivery; ROS; ÎΨm; mitochondrial membrane potential; 3-NP; 3-nitropropionic acid; 6-OHDA; 6-hydroxydopamine; AADC; aromatic-l-amino decarboxyla
Keywords: SNPC; 6-OHDA; 6-hydroxydopamine; AA; Arachidonic; AD; Alzheimer's disease; ALA; α-linolenic acid; ApoE4; Apolipoprotein E4 allele; APP; Amyloid precursor protein; ATP; Adenosine triphosphate; Aβ; Beta-amyloid peptide; CAG; Cytosine-adenine-guanine; DHA;
Keywords: SNPC; Aβ; amyloid β; AADC; L-amino acid decarboxylase; ACC; Anterior cingulate cortex; AD; Alzheimer's disease; aMCI; Amnestic mild cognitive impairment; APP; Amyloid precursor protein; AR; Adrenergic receptor; ATMX; atomoxetine; BDNF; Brain-derived neurotrop
Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility
Keywords: SNPC; BSA; bovine serum albumin; Cal-R; calretinin; Cal-B; calbindin; DAB; 3â²-3â²-diaminobenzidine; GABA; γ-amino butyric acid; GAD; glutamate acid decarboxylase; H2O2; hydrogen peroxide; IHC; immunohistochemistry; MPTP; 1-methyl-4-phenyl-1, 2, 3, 6-tetrahy
A new model to study cell-to-cell transfer of αSynuclein in vivo
Keywords: SNPC; Parkinson's disease; αSynuclein; Cell-to-cell transfer; Sub-cellular compartments; Endoplasmic reticulum; Dopaminergic neuron; αSyn; αSynuclein; αSyn-CGFP; αSynuclein fused to carboxy-terminal; AAV; adeno-associated virus; BiFC; Bi-molecular Fluoresc
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease
Keywords: SNPC; PD; Parkinson's disease; SNpc; substantia nigra pars compacta; PrDs; prion-related disorders; UPR; unfolded protein response; ISR; integrated stress response; PERK; RNA-like ER kinase; ATF4; activating of transcription-4; ATF3; activating of transcription
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease
Keywords: SNPC; 5-HT; serotonin, 6-OHDA, 6-hydroxydopamine; CDNF; cerebral dopamine neurotrophic factor; DA; dopamine; DBS; deep brain stimulation; DOPAC; 3,4-dihydroxyphenylacetic acid; GDNF; glial cell line-derived neurotrophic factor; HVA; homovanillic acid; IBOT; ibo
Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson's disease model in mice
Keywords: SNPC; PD; Parkinson's disease; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNpc; substantia nigra pars compacta; MWM; Morris water maze; Trx-1; Thioredoxin-1; TH; Tyrosine hydroxylase; D1R; D1 receptor; ITL; Initial transfer latency; NR2B; N-methyl-D-as
3,4-Methylenedioxymethamphetamine (MDMA) Alters Synaptic Dopamine Release in the Dorsal Striatum Through Nicotinic Receptors and DAT Inhibition
Keywords: SNPC; CPA; constant potential amperometry; DA; dopamine; DAT; dopamine transporter; DHβE; dihydroβerythroidine; MDMA; 3,4-methylenedioxymethamphetamine; MLA; methyllycaconitine; nAchR; nicotinic acetylcholine receptor; SNpc; substantia nigra pars compact; 3,4
Endurance Exercise Mediates Neuroprotection Against MPTP-mediated Parkinson's Disease via Enhanced Neurogenesis, Antioxidant Capacity, and Autophagy
Keywords: SNPC; BrdU; 5-Bromo-2â²-Deoxyuridine; CuZnSOD; copper zinc superoxide dismutase; DAT; dopamine transporter; DG; dentate gyrus; EE; endurance exercise; GPX; glutathione peroxidase; HO-1; heme oxygenase I; MnSOD; manganese superoxide dismutase; MPTP; 1-methyl-4-
Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model
Keywords: SNPC; α-Syn-P; α-synuclein phosphorylated; Tau-P; tau phosphorylated; mutant; homozygous mutant BD-IV rats; BD-IV; Berlin Druckrey; SD; Sprague Dawley; Myo5a; Myosin5a gene; DA; dopamine; DOPAL; 3,4-dyhydroxyphenyl-acetaldehyde; DOPAC; dihydroxyphenylacetic a
Long Noncoding RNA SNHG1 Promotes Neuroinflammation in Parkinson's Disease via Regulating miR-7/NLRP3 Pathway
Keywords: SNPC; lncRNAs; long noncoding RNAs; LPS; lipopolysaccharide; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NLRP3; nod-like receptor protein 3; PD; Parkinson's disease; SNHG1; small nucleolar RNA host gene 1; SNpc; substantia nigra pars compacta; TNF; tu
REM sleep deprivation and dopaminergic D2 receptors modulation increase recognition memory in an animal model of Parkinson's disease
Keywords: SNPC; DA; Dopamine; NA; Noradrenaline; OF; Open field test; ORT; Object recognition test; PD; Parkinson's disease; PPT; Pedunculopontine tegmental nucleus; REB; Sleep rebound period; REMSD; REM sleep deprivation; SNpc; Substantia nigra pars compacta; Parkinso
miR-494-3p modulates the progression of in vitro and in vivo Parkinson's disease models by targeting SIRT3
Keywords: SNPC; PD; Parkinson's disease; SOD; superoxide dismutase; LDH; lactate dehydrogenase; TNF-α; tumor necrosis factor-α; IL-1β; interleukin-1β; ROS; reactive oxygen species; SNpc; substantia nigra pars compacta; DA; dopaminergic; miRNAs; microRNAs; snRNA; sm
Yeast red pigment modifies cloned human α-synuclein pathogenesis in Parkinson disease models in Saccharomyces cerevisiae and Drosophila melanogaster
Keywords: SNPC; Amyloid; Parkinson's disease; α-synuclein; Red pigment; Yeast; Drosophila; AIR; 1-(5â²-Phosphoribosyl)-5-aminoimidazole; ER; endoplasmic reticulum; FM; the mobile fraction; FRAP; fluorescence recovery after photobleaching; HR, MR, LR; α-synuclein inclu
Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease
Keywords: SNPC; α-Syn; alpha-Synuclein; h-α-Syn; transgenic human alpha-Synuclein; D1 receptor; dopamine receptor type 1; D2 receptor; dopamine receptor type 2; DA; dopamine; DAT; dopamine transporter; VMAT2; vesicular monoamine transporter 2; DOPAC; 3,4-dihydroxypheny
mGlu4 allosteric modulation for treating Parkinson's disease
Keywords: SNPC; Parkinson's disease; Dyskinesia; Glutamate; Dopamine; mGlu4; 6-OHDA; 6-hydroxydopamine; ADX88178; 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine; AIM; abnormal involuntary movements; CODA-RET; complemented donor acceptor reson
Non-cell-autonomous actions of α-synuclein: Implications in glial synucleinopathies
Keywords: SNPC; Astrocyte; Microglia; Neurodegeneration; Neuroinflammation; Parkinson disease; Protein aggregation; Multiple system atrophy; AD; Alzheimer disease; CJD; Creutzfeldt-Jakob disease; CNP; 3â²-cyclic nucleotide 3â²-phosphodiesterase; CSF; cerebrospinal fl
Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease
Keywords: SNPC; Parkinson's disease; Ginsenoside Rb1; Glutamatergic transmission; Glutamate transporters; EAAC1; excitatory amino acid carrier-1; EAATs; excitatory amino acid transporters; GLAST; glutamate/aspartate transporter; GLT-1; glutamate transporter-1; mEPSCs; mi
Effects of α-synuclein on axonal transport
Keywords: SNPC; DLB; Dementia with Lewy Bodies; LB; Lewy Bodies; LN; Lewy neurites; LC; locus coeruleus; PD; Parkinson's disease; SNpc; substantia nigra pars compacta; Axonal transport; Synuclein; Parkinson's disease; Dementia with Lewy Bodies; Lewy Bodies; Lewy neurites
CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons
Keywords: SNPC; LRRK2-G2019S; CRISPR/Cas9; piggyBac; Parkinson's disease; hiPS; α-Synuclein; Serine129 phosphorylated α-Synuclein; PD; Parkinson's disease; LRRK2; leucine-rich repeat kinase 2; G2019S; Glycine 2019 mutated to Serine; SNpc; substantia nigra pars compacta
Neuroprotective effects of total flavonoid fraction of the Epimedium koreanum Nakai extract on dopaminergic neurons: In vivo and in vitro
Keywords: SNPC; DA; dopamine; ERE; estrogen response element; MES23.5; dopaminergic hybridoma cell line; MPP+; 1-methyl-4-phenylpyridinium ion; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD; Parkinson's disease; SN; substantial nigra; SNpc; substantia nigra pars
Subcellular expression of aquaporin-4 in substantia nigra of normal and MPTP-treated mice
Keywords: SNPC; AQP4; aquaporin-4; DA; dopaminergic; GFAP; glial fibrillary acidic protein; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD; Parkinson's disease; SN; substantia nigra; SNpc; substantia nigra pars compacta; TH; tyrosine hydroxylase; aquaporin-4; a
JWA antagonizes paraquat-induced neurotoxicity via activation of Nrf2
Keywords: SNPC; Nrf2; nuclear factor erythroid 2-related factor 2; PQ; paraquat; PD; Parkinson's disease; SA; saline; ROS; reactive oxygen species; JWA-nKO; neuron-specific JWA knockout mice; JWA-nWT; neuron-specific JWA knockout age-matched wild-type mice; SNpc; subst